2026-04-17T03:27:39Zhttps://recercat.cat/oai/request

oai:recercat.cat:11351/71492026-04-04T03:16:08Zcom_2072_378070com_2072_378040col_2072_378092

Effectiveness and Safety of a Single-Dose Ivermectin Treatment for Uncomplicated Strongyloidiasis in Immunosuppressed Patients (ImmunoStrong Study): The Study Protocol Lucas-Dato, Ana Roure, Silvia Arsuaga, Marta Pérez-Jacoiste, Asunción García-Rodríguez, Magdalena Molina Romero, Israel Salvador Velez, Fernando M Institut Català de la Salut [Salvador F, Molina I] Servei de Malalties Infeccioses, Vall d’Hebron Hospital Universitari, Barcelona, Spain. PROSICS Barcelona, Spain. [Lucas-Dato A] Internal Medicine Department, Hospital Vega Baja, 03314 Orihuela, Spain. [Roure S] Infectious Diseases Department, North Metropolitan International Health Unit, Germans Trias i Pujol University Hospital, PROSICS North Metropolitan, 08916 Badalona, Spain. [Arsuaga M] Tropical Medicine Unit, Infectious Diseases Department, La Paz-Carlos III University Hospital, 28046 Madrid, Spain. [Pérez-Jacoiste A] Internal Medicine Department, Hospital Universitario 12 de Octubre, 28041 Madrid, Spain. [García-Rodríguez M] Infectious Diseases Department, Hospital General Universitario de Valencia, 46014 Valencia, Spain Vall d'Hebron Barcelona Hospital Campus Malalties parasitàries - Tractament Avaluació de resultats (Assistència sanitària) DISEASES::Parasitic Diseases::Helminthiasis::Nematode Infections::Secernentea Infections::Rhabditida Infections::Strongyloidiasis Other subheadings::Other subheadings::Other subheadings::/drug therapy ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Diagnosis::Prognosis::Treatment Outcome ENFERMEDADES::enfermedades parasitarias::helmintiasis::infecciones por nematodos::infecciones por Secernentea::infecciones por Rhabditida::estrongiloidiasis Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::diagnóstico::pronóstico::resultado del tratamiento Strongyloides stercoralis; Immunosupressió; Ivermectina Strongyloides stercoralis; Inmunosupresión; Ivermectina Strongyloides stercoralis; Immunosuppression; Ivermectin Strongyloidiasis affects an estimated 600 million people worldwide, especially in tropical and subtropical areas. Single-dose ivermectin treatment has shown to be effective among immunocompetent patients with uncomplicated strongyloidiasis. Here, we present the protocol of the ImmunoStrong study, a prospective observational study aiming to evaluate the effectiveness and safety of a single-dose ivermectin for treatment of uncomplicated strongyloidiasis in immunosuppressed patients. The secondary objectives are to assess accuracy of molecular techniques for the follow-up of these patients and to determine the population pharmacokinetics of ivermectin. The information retrieved by this study will cover relevant information gaps in the strongyloidiasis management among immunosuppressed patients. The present work was supported by the 2020 Research Grant from the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC). 2022-03-11T13:14:36Z 2022-03-11T13:14:36Z 2021-07 info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion Salvador F, Lucas-Dato A, Roure S, Arsuaga M, Pérez-Jacoiste A, García-Rodríguez M, et al. Effectiveness and Safety of a Single-Dose Ivermectin Treatment for Uncomplicated Strongyloidiasis in Immunosuppressed Patients (ImmunoStrong Study): The Study Protocol. Pathogens. 2021 Jul;10(7):812. 2076-0817 https://hdl.handle.net/11351/7149 10.3390/pathogens10070812 34199000 000676425400001 eng Pathogens;10(7) https://doi.org/10.3390/pathogens10070812 Attribution 4.0 International http://creativecommons.org/licenses/by/4.0/ info:eu-repo/semantics/openAccess application/pdf MDPI Scientia